New eye drug trial hopes to slow vision loss from dry AMD
NCT ID NCT07160179
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment (SYFOVRE) to check safety and how well it works. The trial lasts about 22 months with regular clinic visits and eye exams.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Retina Consultants - The Woodlands /ID# 262138
RECRUITINGThe Woodlands, Texas, 77384, United States
-
Retina Foundation of the Southwest /ID# 262479
RECRUITINGDallas, Texas, 75231, United States
-
Retina Partners Midwest, P.C. /ID# 262172
RECRUITINGCarmel, Indiana, 46032, United States
-
Retina Research Institute of Texas /ID# 262141
RECRUITINGAbilene, Texas, 79606-1224, United States
-
Sierra Eye Associates /ID# 262142
RECRUITINGReno, Nevada, 89502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a VR maze reveal hidden vision loss in macular degeneration?
- New eye imaging could reveal hidden clues to vision loss
- Can a new eye injection save vision in wet AMD?
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness